Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With
Go back to Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With| (NASDAQ: LTRN) | Delayed: 3.88 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.88 | 52 Week High | $ | |||
| Open | $3.88 | 52 Week Low | $ | |||
| Day High | $3.88 | P/E | N/A | |||
| Day Low | $3.88 | EPS | $ | |||
| Volume | 164 | |||||
